Institution
University of Catania
Education•Catania, Italy•
About: University of Catania is a education organization based out in Catania, Italy. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 14599 authors who have published 41195 publications receiving 1032705 citations. The organization is also known as: Università degli Studi di Catania & Universita degli Studi di Catania.
Papers published on a yearly basis
Papers
More filters
••
Vita-Salute San Raffaele University1, University of Ferrara2, University of Turin3, Complutense University of Madrid4, Hospital Universitario de Canarias5, Copenhagen University Hospital6, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico7, St James's University Hospital8, University of Verona9, The Royal Marsden NHS Foundation Trust10, Universitaire Ziekenhuizen Leuven11, University of Modena and Reggio Emilia12, Rabin Medical Center13, First Faculty of Medicine, Charles University in Prague14, University of Eastern Piedmont15, Albert Schweitzer Hospital16, Policlinico Umberto I17, Trinity College, Dublin18, University of Padua19, Shaare Zedek Medical Center20, University of Milan21, Tel Aviv Sourasky Medical Center22, Ludwig Maximilian University of Munich23, University of Amsterdam24, University of Perugia25, Qatar Airways26, Semmelweis University27, University of Catania28, University of Bern29, National and Kapodistrian University of Athens30, Norwich University31, Carol Davila University of Medicine and Pharmacy32, Peter MacCallum Cancer Centre33, Iuliu Hațieganu University of Medicine and Pharmacy34
TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Abstract: Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
189 citations
••
TL;DR: Nut consumption is associated with lower risk of all-cause, CVD, and cancer mortality, but the presence of confounding factors should be taken into account when considering such findings.
189 citations
••
TL;DR: In this article, the LHC proton-proton collisions at √s=7'TeV, corresponding to 5.0'fb-1 of integrated luminosity, have been collected with the CMS detector.
Abstract: Measurements of inclusive jet and dijet production cross sections are presented. Data from LHC proton-proton collisions at √s=7 TeV, corresponding to 5.0 fb-1 of integrated luminosity, have been collected with the CMS detector. Jets are reconstructed up to rapidity 2.5, transverse momentum 2 TeV, and dijet invariant mass 5 TeV, using the anti-kT clustering algorithm with distance parameter R=0.7. The measured cross sections are corrected for detector effects and compared to perturbative QCD predictions at next-to-leading order, using five sets of parton distribution functions.
189 citations
••
TL;DR: Etanercept therapy over 12 weeks demonstrated only a small but significant improvement in asthma control and systemic inflammation, as measured by serum albumin and CRP.
Abstract: Aim: Tumour necrosis factor α (TNFα) is a cytokine recognised as a therapeutic target in chronic inflammatory diseases. Methods: A randomised, double blind, placebo controlled parallel group trial is reported of etanercept (an IgG1-TNF p75 receptor fusion protein), administered once weekly for 12 weeks in 39 patients with severe corticosteroid refractory asthma. Efficacy was measured by change from the pretreatment baseline in Asthma Related Quality of Life (AQLQ) and Asthma Control (ACQ) Questionnaire scores (the primary endpoints), lung function, peak expiratory flow (PEF) and bronchial hyperresponsiveness (BHR). Sputum and serum inflammatory cells and cytokines, serum albumin and C reactive protein (CRP) as biomarkers of inflammation were also assessed. Results: There was a small but significant difference in reduction of ACQ scores between treatment and placebo (−1.11 (95% CI −1.56 to −0.75) and −0.52 (95% CI −0.97 to −0.07), respectively, p = 0.037). There was no significant difference in improvements in AQLQ scores, lung function, PEF, BHR or exacerbation rates between the groups. Minor adverse events, including injection site pain and skin rashes, were more frequent with etanercept. There was a significant reduction in sputum macrophages and CRP, and increases in serum TNFα and albumin following treatment, but not in other laboratory parameters. Conclusion: Etanercept therapy over 12 weeks demonstrated only a small but significant improvement in asthma control and systemic inflammation, as measured by serum albumin and CRP. Larger randomised, placebo controlled trials are required to clarify the role of TNFα antagonism in subjects with severe refractory asthma.
189 citations
••
TL;DR: In this paper, the authors search for high-energy neutrinos from the binary neutron star merger in the GeV-EeV energy range using the Antares, IceCube, and Pierre Auger Observatories.
Abstract: The Advanced LIGO and Advanced Virgo observatories recently discovered gravitational waves from a binary neutron star inspiral. A short gamma-ray burst (GRB) that followed the merger of this binary was also recorded by the Fermi Gamma-ray Burst Monitor (Fermi-GBM), and the Anti-Coincidence Shield for the Spectrometer for the International Gamma-Ray Astrophysics Laboratory (INTEGRAL), indicating particle acceleration by the source. The precise location of the event was determined by optical detections of emission following the merger. We searched for high-energy neutrinos from the merger in the GeV–EeV energy range using the Antares, IceCube, and Pierre Auger Observatories. No neutrinos directionally coincident with the source were detected within ±500 s around the merger time. Additionally, no MeV neutrino burst signal was detected coincident with the merger. We further carried out an extended search in the direction of the source for high-energy neutrinos within the 14 day period following the merger, but found no evidence of emission. We used these results to probe dissipation mechanisms in relativistic outflows driven by the binary neutron star merger. The non-detection is consistent with model predictions of short GRBs observed at a large off-axis angle.
189 citations
Authors
Showing all 14771 results
Name | H-index | Papers | Citations |
---|---|---|---|
Napoleone Ferrara | 167 | 494 | 140647 |
Tobin J. Marks | 159 | 1621 | 111604 |
Susan O'Brien | 145 | 1509 | 87813 |
Stephen T. Holgate | 142 | 870 | 82345 |
Y. Choi | 141 | 1631 | 98709 |
Michael J. Keating | 140 | 1169 | 76353 |
Tiziano Rovelli | 135 | 1441 | 90518 |
Francesco Navarria | 135 | 1535 | 91427 |
Francesca Romana Cavallo | 135 | 1571 | 92392 |
Alessia Tricomi | 133 | 1446 | 92375 |
Burak Bilki | 132 | 1227 | 83478 |
Andrea Castro | 132 | 1500 | 90019 |
Paolo Capiluppi | 131 | 1544 | 89643 |
Daniele Bonacorsi | 130 | 1381 | 85994 |
Vitaliano Ciulli | 129 | 1171 | 82045 |